This study is now closed to enrollment. All of us here at the Health-eBrain Study would like to give a huge thank you to the caregivers who participated in this important brain health research! Your efforts will go a long way in helping us understand how the caregiving experience impacts brain performance, cognitive vitality, and mental health. Through this research, we will be able to better support the cognitive health of caregivers everywhere. YOU CARE. AND WE CARE ABOUT YOU.
Join The Study
If you have previously registered on the Health eBrain website prior to July 26, 2016 please re-register
The Health-eBrain study is supported by the BrightFocus Foundation and the Geoffrey Beene Foundation Alzheimer’s Initiative, lead funders under the 21st century BrainTrust(21CBT), designed to empower personal brain health and support early diagnosis using mHealth technology.

Caregiving has been shown to have a negative effect on the mental and physical health of the caregiver.

AnthroTronix, in partnership with Mindoula, would like to gather information on Alzheimer’s caregivers’ mental and cognitive health in order to learn more about the caregiver experience and to better understand how to support caregivers.

How does it work?
It’s very easy to participate!

You will sign up to take a set of 3 surveys that should last no more than 30 minutes that you may take at your convenience.

Study enrollment will last a total of 12 weeks for eligible participants. After being enrolled, you will be invited to begin participation in one of the following:

Some participants will receive the Mindoula Android or iPhone application for free, a case management app that will:

In this version of the study, you will also take the DANA application, which involves a short test that will track your cognitive performance.

DANA Wellness
Participants who do not receive Mindoula will receive the DANA application with or without accompanying wellness snapshots.

These snapshots will track and report your:

Am I eligible to participate?
The study is open to informal* caregivers who provide care to someone with Alzheimer’s disease. Eligibility varies for each study section.

Overall Participants must be:

Additional criteria applies for each participation section for further information please review the FAQ section and/or contact the study coordinator. Additional details are provided in the consent form before enrolling in the study.

You cannot participate if you:

(*An informal caregiver is defined as a person without formal training who provides care within or outside the home for an individual)

Join us and help researchers better understand the impact of caregiving!

Please help us help caregivers by taking part in this study!


Our Partners

Research Team

anthrotronix_logo About AnthroTronix
AnthroTronix, an engineering research and development company, produces human-centered technologies that advance health, communication, education, and defense. We develop innovative, research-based technologies that influence change and enhance lives around the world. Our company has been recognized among Inc.Magazine’s “5000 Fastest Growing Companies” and selected by the World Economic Forum as a Technology Pioneer company. For more information on us, visit, follow us on Twitter at @AnthroTronix, or connect with us on LinkedIn.

DANA, which received FDA clearance in October 2014, is a mobile medical app that can be used on a phone or tablet and works on both the Android and iOS operating systems. DANA administers game-like tests that can provide data within minutes to help assess and measure a person’s brain/cognitive health. The app can help clinicians track cognitive function as a quantitative outcome during treatment for such conditions as depression, dementia/Alzheimer’s Disease, and Post-Traumatic Stress Disorder (PTSD). For more information on DANA, visit

mindoula About Mindoula
Mindoula ( is a technology-enabled case management company headquartered in Silver Spring, Maryland, that provides 24/7 virtual and in-person support to individuals and families facing behavioral health challenges . Its proprietary telehealth platform, which includes a HIPAA compliant mobile engagement app,proprietary psychometrics,predictive analytics,and collaborative care software, enables its team of case managers and peer support specialists to deliver market leading behavioral health outcome improvements and reduce healthcare costs. An innovator in the areas of case management, collaborative care, and behavioral health population management, Mindoula is at the forefront of the transformation of behavioral healthcare.

Funding Partners

BrightFocusBrightFocus Foundation
BrightFocus Foundation funds research and promotes awareness to end Alzheimer’s disease, macular degeneration and glaucoma. The nonprofit is current l y managing a global portfolio of 150 projects, efforts that were recommended by scientific review committees of leading experts. For more information, visit

unnamed About the Geoffrey Beene Foundation Alzheimer’s Initiative
The Geoffrey Beene Foundation Alzheimer’s Initiative is a catalytic donor philanthropy that promotes innovation in early diagnosis and AD prevention. Funded by the Geoffrey Beene Foundation since 2008, it has launched major innovation challenges, national public service campaigns and led the formation in 2012 of the non-profit partnership, 21st Century BrainTrust.Partners: Geoffrey Beene Foundation Alzheimer’s Initiative, BrightFocus Foundation, UsAgainstAlzheimers and the Cleveland Clinic/Lou Ruvo Brain Institute.

About the 21st Century Brain Trust

The health-eBrain study is supported by BrightFocus Foundation and Geoffrey Beene Foundation Alzheimer's Initiative, lead partners in the 21st Century BrainTrust. DANA and Mindoula are co-Principal Investigators. 21st Century BrainTrust® (21CBT) is a virtual research ecosystem designed to empower personal brain health and support early diagnosis using self-administered mobile applications for personal measurement and monitoring of cognition. 21CBT supports novel technologies that offer low-cost screening capabilities for future prevention trials to facilitate enrollment as well as exploratory trial endpoints.